Literature DB >> 11102406

Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alteration.

V T Cao1, G Arlet, B M Ericsson, A Tammelin, P Courvalin, T Lambert.   

Abstract

Klebsiella pneumoniae BM2974 isolated from an abdominal abcess was resistant to high concentrations of all available beta-lactams, including recently developed third-generation cephalosporins and carbapenems. Isoelectric focusing of beta-lactamases and amplification, cloning and sequencing of the corresponding genes, together with conjugation and transformation experiments, indicated that, in addition to the chromosomally encoded beta-lactamase, the strain produced three plasmid-mediated beta-lactamases with pIs of 5.4, 8.2 and 9.0, which corresponded to TEM-1, SHV-5 and AmpC-type CMY-4, respectively. Strain BM2974 also lacked a major outer membrane protein of c. 40 kDa which was present in the spontaneous imipenem-susceptible revertant BM2974-1. We suggest that imipenem resistance in strain BM2974 is attributable to production of CMY-4 beta-lactamase combined with permeability alteration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11102406     DOI: 10.1093/jac/46.6.895

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  29 in total

1.  What constitutes an extended-spectrum beta-lactamase?

Authors:  C Jeffrey Smith
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 2.  Plasmid-determined AmpC-type beta-lactamases.

Authors:  Alain Philippon; Guillaume Arlet; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  In vivo acquisition of high-level resistance to imipenem in Escherichia coli.

Authors:  Laurent Poirel; Claire Héritier; Colette Spicq; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

4.  Concurrent occurrence of blaampC families and blaCTX-M genogroups and association with mobile genetic elements ISEcp1, IS26, ISCR1, and sul1-type class 1 integrons in Escherichia coli and Klebsiella pneumoniae isolates originating from India.

Authors:  Mohammed Shahid; Farrukh Sobia; Anuradha Singh; Haris M Khan
Journal:  J Clin Microbiol       Date:  2012-02-15       Impact factor: 5.948

5.  Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase.

Authors:  Jimena Alba; Yoshikazu Ishii; Kenneth Thomson; Ellen Smith Moland; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

6.  Genetic context of plasmid-carried blaCMY-2-like genes in Enterobacteriaceae.

Authors:  C Verdet; V Gautier; E Chachaty; E Ronco; N Hidri; D Decré; G Arlet
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

7.  Diagnostic Accuracy of BD Phoenix CPO Detect for Carbapenemase Production in 190 Enterobacteriaceae Isolates.

Authors:  Chiou Horng Ong; Lasantha Ratnayake; Michelle L T Ang; Raymond Tzer Pin Lin; Douglas Su Gin Chan
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

8.  Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development.

Authors:  Ana Mena; Virginia Plasencia; Laura García; Olga Hidalgo; José Ignacio Ayestarán; Sebastián Alberti; Nuria Borrell; José L Pérez; Antonio Oliver
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 9.  Past and Present Perspectives on β-Lactamases.

Authors:  Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

10.  Evaluation of boronic acid disk tests for differentiating KPC-possessing Klebsiella pneumoniae isolates in the clinical laboratory.

Authors:  Athanassios Tsakris; Ioulia Kristo; Aggeliki Poulou; Katerina Themeli-Digalaki; Alexandros Ikonomidis; Dimitra Petropoulou; Spyros Pournaras; Danai Sofianou
Journal:  J Clin Microbiol       Date:  2008-12-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.